Global Injectable Seizure Drugs Market
Global Injectable Seizure Drugs Market

Injectable Seizure Drugs Comprehensive Study by Type (Fosphenytoin, Midazolam, Carbamazepine, Cenobamate, Gabapentin, Phenytoin, Lamotrigine, Topiramate, Levetiracetam, Clobazam, Diazepam, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Seizure Type (Generalized seizures (Absence Seizures, Tonic-Clonic Seizures), Focal Seizures), Therapy Type (Monotherapy, Combination Therapy)

Injectable Seizure Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 223 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Injectable Seizure Drugs Market Scope?
Seizures, a major symptom of epilepsy, are defined as abnormal paroxysmal electrical disorders of cortical neural networks. Many anti-epileptic drugs work in some way by reducing neuronal excitability (sodium and calcium channel modulation) or increasing the inhibition of neurons by interacting in different parts of am-aminobutyric acid receptors. It is believed that many injectable seizure drugs act as a result of several simultaneous processes in both the excitatory and inhibitory structures. Epilepsy affects nearly 3 million people in the United States, with nearly 500 new cases of epilepsy being diagnosed each day. The median incidence of acute symptomatic seizures is 29Ė39 per 100,000 per year. Given the increasing number of epileptic seizures due to greater exposure to perinatal risk factors and a higher rate of CNS disease, the injectable seizure market is the leading dosage form choice for treating seizures. Injectable seizure medications are important in treating emergencies of clinical seizure emergencies and in other treatments that cannot be administered orally. The injectable seizure medications provide quick and complete delivery (through blood vessels) or near-complete (muscle building) bioavailability. Controlled administration of the injectable seizure medication is possible with intravenous, but not intramuscular, formulations.

The Injectable Seizure Drugs market study is being classified by Type (Fosphenytoin, Midazolam, Carbamazepine, Cenobamate, Gabapentin, Phenytoin, Lamotrigine, Topiramate, Levetiracetam, Clobazam, Diazepam and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Injectable Seizure Drugs market throughout the predicted period.

Sanofi (France), Pfizer Inc. (United States), GW Pharmaceuticals plc (United Kingdom), UCB S.A. (Belgium), Eisai Co.Ltd. (Japan), Sunovion Pharmaceuticals Inc. (United States), H. Lundbeck A/S (Denmark), GlaxoSmithKline plc (United Kingdom), Sandoz Inc. (Germany), Omega Laboratories Ltd (United States), Fresenius Kabi (Germany), Mylan Pharmaceuticals (United States) and Roche Holding AG (Switzerland) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Injectable Seizure Drugs market by Type, Application and Region.

On the basis of geography, the market of Injectable Seizure Drugs has been segmented into .

Xeris Pharma had received FDA approval for its diazepam formulation for the treatment of acute repetitive seizures, also known as cluster seizures, for Phase III clinical trial. and Sedor Pharmaceuticals, LLC, had received FDA approval for fosphenytoin sodium for injection in status epilepticus in adult and pediatric patients.


Influencing Market Trend
  • The Rising Demand for Preventing or Controlling Epileptic Seizures
  • Improvement in Health Care Reforms

Market Drivers
  • Increasing Acceptance of Novel and Cost-Effective Treatments
  • The Rising Prevalence of Seizures
  • Increasing Cases of Accidents and Injuries
  • The Rising Patient Awareness Regarding Effective Treatment of Epilepsy

Opportunities
  • A Rise in Investment in Research Activities to Develop More Injectable Seizure Drugs
  • The Growing Pharmaceutical Companies

Restraints
  • The Illicit Use of Anti-Seizure Drugs
  • The Least Awareness of the Seizure as a Disorder
  • Stringent Regulations and the Lack of FDA Approvals in Some Regions

Challenges
  • Marketing Of an Unapproved Drug
  • Recall of Drug by the FDA


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Injectable Seizure Drugs, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Injectable Seizure Drugs market expands?
The Global Injectable Seizure Drugs market is expected to see a growth of % during projected year 2020 to 2026.

2. Who are the prominent players of the Global Injectable Seizure Drugs market?
The prominent players of Global Injectable Seizure Drugs market are Sanofi (France), Pfizer Inc. (United States), GW Pharmaceuticals plc (United Kingdom), UCB S.A. (Belgium), Eisai Co.Ltd. (Japan), Sunovion Pharmaceuticals Inc. (United States), H. Lundbeck A/S (Denmark), GlaxoSmithKline plc (United Kingdom), Sandoz Inc. (Germany), Omega Laboratories Ltd (United States), Fresenius Kabi (Germany), Mylan Pharmaceuticals (United States) and Roche Holding AG (Switzerland), to name a few.

3. What are the top priorities to focus for Injectable Seizure Drugs marketís growth?
In this highly competitive & fast evolving Injectable Seizure Drugs industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Fosphenytoin
  • Midazolam
  • Carbamazepine
  • Cenobamate
  • Gabapentin
  • Phenytoin
  • Lamotrigine
  • Topiramate
  • Levetiracetam
  • Clobazam
  • Diazepam
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Seizure Type
  • Generalized seizures [Absence Seizures, Tonic-Clonic Seizures]
  • Focal Seizures

By Therapy Type
  • Monotherapy
  • Combination Therapy

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Increasing Acceptance of Novel and Cost-Effective Treatments
        • 3.2.2. The Rising Prevalence of Seizures
        • 3.2.3. Increasing Cases of Accidents and Injuries
        • 3.2.4. The Rising Patient Awareness Regarding Effective Treatment of Epilepsy
      • 3.3. Market Challenges
        • 3.3.1. Marketing Of an Unapproved Drug
        • 3.3.2. Recall of Drug by the FDA
      • 3.4. Market Trends
        • 3.4.1. The Rising Demand for Preventing or Controlling Epileptic Seizures
        • 3.4.2. Improvement in Health Care Reforms
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Injectable Seizure Drugs, by Type, Distribution Channel, Seizure Type and Therapy Type (value and price ) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global Injectable Seizure Drugs (Value)
        • 5.2.1. Global Injectable Seizure Drugs by: Type (Value)
          • 5.2.1.1. Fosphenytoin
          • 5.2.1.2. Midazolam
          • 5.2.1.3. Carbamazepine
          • 5.2.1.4. Cenobamate
          • 5.2.1.5. Gabapentin
          • 5.2.1.6. Phenytoin
          • 5.2.1.7. Lamotrigine
          • 5.2.1.8. Topiramate
          • 5.2.1.9. Levetiracetam
          • 5.2.1.10. Clobazam
          • 5.2.1.11. Diazepam
          • 5.2.1.12. Others
        • 5.2.2. Global Injectable Seizure Drugs by: Distribution Channel (Value)
          • 5.2.2.1. Hospital Pharmacies
          • 5.2.2.2. Retail Pharmacies
          • 5.2.2.3. Online Pharmacies
          • 5.2.2.4. Others
        • 5.2.3. Global Injectable Seizure Drugs by: Seizure Type (Value)
          • 5.2.3.1. Generalized seizures [Absence Seizures, Tonic-Clonic Seizures]
          • 5.2.3.2. Focal Seizures
        • 5.2.4. Global Injectable Seizure Drugs by: Therapy Type (Value)
          • 5.2.4.1. Monotherapy
          • 5.2.4.2. Combination Therapy
      • 5.3. Global Injectable Seizure Drugs (Price)
        • 5.3.1. Global Injectable Seizure Drugs by: Type (Price)
    • 6. Injectable Seizure Drugs: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Sanofi (France)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. Pfizer Inc. (United States)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. GW Pharmaceuticals plc (United Kingdom)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. UCB S.A. (Belgium)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Eisai Co.Ltd. (Japan)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Sunovion Pharmaceuticals Inc. (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. H. Lundbeck A/S (Denmark)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. GlaxoSmithKline plc (United Kingdom)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Sandoz Inc. (Germany)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Omega Laboratories Ltd (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
        • 6.4.11. Fresenius Kabi (Germany)
          • 6.4.11.1. Business Overview
          • 6.4.11.2. Products/Services Offerings
          • 6.4.11.3. Financial Analysis
          • 6.4.11.4. SWOT Analysis
        • 6.4.12. Mylan Pharmaceuticals (United States)
          • 6.4.12.1. Business Overview
          • 6.4.12.2. Products/Services Offerings
          • 6.4.12.3. Financial Analysis
          • 6.4.12.4. SWOT Analysis
        • 6.4.13. Roche Holding AG (Switzerland)
          • 6.4.13.1. Business Overview
          • 6.4.13.2. Products/Services Offerings
          • 6.4.13.3. Financial Analysis
          • 6.4.13.4. SWOT Analysis
    • 7. Global Injectable Seizure Drugs Sale, by Type, Distribution Channel, Seizure Type and Therapy Type (value and price ) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global Injectable Seizure Drugs (Value)
        • 7.2.1. Global Injectable Seizure Drugs by: Type (Value)
          • 7.2.1.1. Fosphenytoin
          • 7.2.1.2. Midazolam
          • 7.2.1.3. Carbamazepine
          • 7.2.1.4. Cenobamate
          • 7.2.1.5. Gabapentin
          • 7.2.1.6. Phenytoin
          • 7.2.1.7. Lamotrigine
          • 7.2.1.8. Topiramate
          • 7.2.1.9. Levetiracetam
          • 7.2.1.10. Clobazam
          • 7.2.1.11. Diazepam
          • 7.2.1.12. Others
        • 7.2.2. Global Injectable Seizure Drugs by: Distribution Channel (Value)
          • 7.2.2.1. Hospital Pharmacies
          • 7.2.2.2. Retail Pharmacies
          • 7.2.2.3. Online Pharmacies
          • 7.2.2.4. Others
        • 7.2.3. Global Injectable Seizure Drugs by: Seizure Type (Value)
          • 7.2.3.1. Generalized seizures [Absence Seizures, Tonic-Clonic Seizures]
          • 7.2.3.2. Focal Seizures
        • 7.2.4. Global Injectable Seizure Drugs by: Therapy Type (Value)
          • 7.2.4.1. Monotherapy
          • 7.2.4.2. Combination Therapy
      • 7.3. Global Injectable Seizure Drugs (Price)
        • 7.3.1. Global Injectable Seizure Drugs by: Type (Price)
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Injectable Seizure Drugs: by Type(USD Million)
    • Table 2. Injectable Seizure Drugs: by Distribution Channel(USD Million)
    • Table 3. Injectable Seizure Drugs: by Seizure Type(USD Million)
    • Table 4. Injectable Seizure Drugs: by Therapy Type(USD Million)
    • Table 5. Injectable Seizure Drugs: by Type(USD/Units)
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Company Basic Information, Sales Area and Its Competitors
    • Table 19. Injectable Seizure Drugs: by Type(USD Million)
    • Table 20. Injectable Seizure Drugs: by Distribution Channel(USD Million)
    • Table 21. Injectable Seizure Drugs: by Seizure Type(USD Million)
    • Table 22. Injectable Seizure Drugs: by Therapy Type(USD Million)
    • Table 23. Injectable Seizure Drugs: by Type(USD/Units)
    • Table 24. Research Programs/Design for This Report
    • Table 25. Key Data Information from Secondary Sources
    • Table 26. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Injectable Seizure Drugs: by Type USD Million (2015-2020)
    • Figure 5. Global Injectable Seizure Drugs: by Distribution Channel USD Million (2015-2020)
    • Figure 6. Global Injectable Seizure Drugs: by Seizure Type USD Million (2015-2020)
    • Figure 7. Global Injectable Seizure Drugs: by Therapy Type USD Million (2015-2020)
    • Figure 8. Global Injectable Seizure Drugs: by Type USD/Units (2015-2020)
    • Figure 9. Global Injectable Seizure Drugs share by Players 2020 (%)
    • Figure 10. Global Injectable Seizure Drugs share by Players (Top 3) 2020(%)
    • Figure 11. Global Injectable Seizure Drugs share by Players (Top 5) 2020(%)
    • Figure 12. BCG Matrix for key Companies
    • Figure 13. Sanofi (France) Revenue, Net Income and Gross profit
    • Figure 14. Sanofi (France) Revenue: by Geography 2020
    • Figure 15. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 16. Pfizer Inc. (United States) Revenue: by Geography 2020
    • Figure 17. GW Pharmaceuticals plc (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 18. GW Pharmaceuticals plc (United Kingdom) Revenue: by Geography 2020
    • Figure 19. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
    • Figure 20. UCB S.A. (Belgium) Revenue: by Geography 2020
    • Figure 21. Eisai Co.Ltd. (Japan) Revenue, Net Income and Gross profit
    • Figure 22. Eisai Co.Ltd. (Japan) Revenue: by Geography 2020
    • Figure 23. Sunovion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 24. Sunovion Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
    • Figure 25. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
    • Figure 26. H. Lundbeck A/S (Denmark) Revenue: by Geography 2020
    • Figure 27. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 28. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
    • Figure 29. Sandoz Inc. (Germany) Revenue, Net Income and Gross profit
    • Figure 30. Sandoz Inc. (Germany) Revenue: by Geography 2020
    • Figure 31. Omega Laboratories Ltd (United States) Revenue, Net Income and Gross profit
    • Figure 32. Omega Laboratories Ltd (United States) Revenue: by Geography 2020
    • Figure 33. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
    • Figure 34. Fresenius Kabi (Germany) Revenue: by Geography 2020
    • Figure 35. Mylan Pharmaceuticals (United States) Revenue, Net Income and Gross profit
    • Figure 36. Mylan Pharmaceuticals (United States) Revenue: by Geography 2020
    • Figure 37. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
    • Figure 38. Roche Holding AG (Switzerland) Revenue: by Geography 2020
    • Figure 39. Global Injectable Seizure Drugs: by Type USD Million (2021-2026)
    • Figure 40. Global Injectable Seizure Drugs: by Distribution Channel USD Million (2021-2026)
    • Figure 41. Global Injectable Seizure Drugs: by Seizure Type USD Million (2021-2026)
    • Figure 42. Global Injectable Seizure Drugs: by Therapy Type USD Million (2021-2026)
    • Figure 43. Global Injectable Seizure Drugs: by Type USD/Units (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • Sanofi (France)
    • Pfizer Inc. (United States)
    • GW Pharmaceuticals plc (United Kingdom)
    • UCB S.A. (Belgium)
    • Eisai Co.Ltd. (Japan)
    • Sunovion Pharmaceuticals Inc. (United States)
    • H. Lundbeck A/S (Denmark)
    • GlaxoSmithKline plc (United Kingdom)
    • Sandoz Inc. (Germany)
    • Omega Laboratories Ltd (United States)
    • Fresenius Kabi (Germany)
    • Mylan Pharmaceuticals (United States)
    • Roche Holding AG (Switzerland)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation